Skip to main content
. 2008 Jul 16;2008(3):CD006297. doi: 10.1002/14651858.CD006297.pub2
Characteristic Schober 2001 Tunbridge 1989 Zinman 1999 Rossetti 2003 Vague 2003
Intervention 1 (I1) / intervention 2 (I2) / control 1 (C1) I1: Glargine + HI 
 C1: NPH + HI I1: Ultralente + HI 
 C1: Lente + HI I1: Ultralente + Lispro 
 C1: NPH + Lispro I1: Glargine dinnertime + Lispro 
 I2: Glargine bedtime + Lispro 
 C: NPH + Lispro I1: Detemir + Aspart 
 C: NPH + Aspart
[n] (I1/ I2 / C1 / total) 174/175/349 66/66/66 87/91/178 17/17/17/54 301/146/447
Sex (male) [n,%] ? 37, 56% 41, 47% / 35, 38* 9, 52% / 8, 47% / 10, 58% 162, 53% / 74, 50.7%
Age [years] mean (SD) 11.8 (2) / 11.5 (2) 38 (range 18‐62) 35 (1) / 35 (1) 32 (3) / 31.3 (3.4) / 34 (3.1) 38.9 (13.3) / 41.8 (14.2)
Ethnic groups [%] ? ? ? ? ?
Duration of disease [years] mean (SD) ? 14 (range 3‐30) 13.6 (0.8) / 16.1 (1.1) 13.1 (1.9) / 12.9 (2.3) / 14.8 (2.3) 17.1 (9.9) / 17.4 (11)
Body mass index [kg/m2] mean (SD) 
 
 Weight [kg] mean (SD) 18.8 (2) / 18.9 ( 2) 25.3 (range 18.6‐33.4) 
 
 Kg: 73.0 (range 45.6‐99.0) 25 (1) / 25 (1) 
 
 Kg: 74 (1) / 75 (1) 23.1 (0.8) / 22.9 (1) / 23.2 (0.9) 24.5 (3.2) / 24.6 (3.4) 
 
 Kg: 71.5 (11.9) / 71.2 (11.5)
Pharmaco‐naive patients [n,%] 0 / 0 0 / 0 0 / 0 0/0/0 0/0/0
HbA1c [%] mean (SD) ? (all <12%) 9.0 (range 6.6‐11.4) 8.2 (0.1) / 8.2 (0.1) 6.9 (0.1) / 6.8 (0.2) / 7 (0.2) 8.18 (1.14) / 8.11 (1.12)
Fasting blood glucose ? ? ? ? ?
Fasting plasma glucose ? ? ? ? 11.6 (5.21) / 11.6 (5.27)
Basal insulin dose (IU/day) ? ? ? ? 27.4 (12.5) / 25.2 (13.7)
Bolus insulin dose (IU/day) ? ? ? ? 30.9 (15.5) / 29.6 (15.8)
Clinically different baseline characteristics (Y/N) N NA NA N N
Notes letter publication crossover trial      
Symbols & abbreviations: Y = yes; N = no; ? = unclear 
 I = intervention; C = control